LOGIN
ID
PW
MemberShip
2023-12-07 13:35
All News
Policy
Company
Product
Opinion
InterView
°Ë»ö
Dailypharm Live Search
Close
Policy
Severe asthma txs Nucala and Cinqair are to be reimbursed
by
Lee, Jeong-Hwan
Oct 24, 2023 05:22am
Reimbursement treatment options for the treatment of severe eosinophilic asthma are expanded. GSK Korea's Nucala and Handok Teva Cinqair will be listed on the payroll simultaneously next month. Eisai's JAK inhibitor Jyseleca will also have new insurance coverage standards, and Novartis' JAK1/JAK2 inhibitor Jakavi will have coverage standards
Policy
TZD combined DPP4i-SGLT2i complex
by
Lee, Tak-Sun
Oct 24, 2023 05:21am
Due to the expansion of the reimbursement standards for combination diabetes drugs, combination drugs combining TZD-based ingredients with DPP4i or SGLT2i are expected to be released in November. Most of these products are combination drugs combining the DPP4i series Sitagliptin. According to the industry on the 23rd, TZD combination drugs s
Policy
Announcement of dual pricing system
by
Lee, Jeong-Hwan
Oct 20, 2023 05:32am
The Ministry of Health and Welfare is expected to include the application of a refund-type risk-sharing system for innovative new drugs in the plan to provide appropriate information on the innovative value of new drugs to be announced soon. In order to improve accessibility to rare disease treatments, the company announced its position to c
Policy
Will a new Alzheimer¡¯s drug be introduced in 20 yrs in KOR?
by
Lee, Tak-Sun
Oct 20, 2023 05:31am
New Alzheimer's disease treatments are accelerating their introduction into the country. Following Eisai's application for the approval of its ¡®lecanemab¡¯ in June, Lilly also received approval from the Ministry of Food and Drug Safety to initiate a multinational Phase 3 clinical trial for ¡®donanemab¡¯ in Korea. As Biogen applied to
Policy
HIRA ¡®will discuss reimb obesity treatments with MOHW'
by
Lee, Tak-Sun
Oct 19, 2023 05:29am
In response to the claim that obesity should be recognized as a chronic disease and its treatment covered by Korea¡¯s health insurance, President Jung-gu Kang of the Health Insurance Review and Assessment Service responded that he would discuss the request with the Ministry of Health and Welfare. Kang made this announcement at the Natio
Policy
NA calls for prompt reimb of Ilaris during NA audit
by
Lee, Tak-Sun
Oct 19, 2023 05:29am
The National Assembly requested progress to be made in reimbursing ¡®Ilaris (canakinumab, Novartis),¡¯ a drug used to treat Hereditary recurrent fever syndromes that affect 13 patients in Korea. Rep. Sun-Woo Kang of the Democratic Party of Korea and member of the National Assembly Health and Welfare Committee suggested so at the Health I
Policy
Rep. Young-hee Choi ¡®expenses surged after Moon Care¡¯
by
Lee, Tak-Sun
Oct 18, 2023 05:49am
After the implementation of Moon Jae-in Care, which was implemented to strengthen health insurance coverage, KRW 5.272 trillion was found to have been spent on drugs for seriously ill patients over the 6 years and exceeded the expenditure target every year. According to data Rep. Choi Young-hee (People Power Party, proportional representa
Policy
Layla+Celecoxib coming soon
by
Lee, Tak-Sun
Oct 18, 2023 05:48am
A compound that combines different osteoarthritis treatments based on natural products and synthesis is expected to be released on the 1st of next month. 20 companies are selling their products, and it is noteworthy whether it will create a new wind in the osteoarthritis treatment market. The original drug ingredient of Danggui, Mogwa, Bangp
Policy
Pharma-Bio Control Tower launched¡¦first meeting next month
by
Lee, Jeong-Hwan
Oct 18, 2023 05:48am
A presidential order to establish the Biohealth Innovation Committee, a control tower to foster the pharmaceutical bio-industry, has been issued. The government plans to hold its first meeting next month to begin discussing major agendas. With the launch of a pan-ministerial organization, financial and administrative support is expected to be
Policy
Daewoong's new diabetes drug 'Envlo',
by
Lee, Tak-Sun
Oct 17, 2023 05:28am
Envlo, a new diabetes drug developed by Daewoong Pharmaceutical, is entering long-term safety and efficacy testing of the Zemiglo three-drug therapy. While triple therapy of the Metformin+SGLT2i+DPP4i has been approved for reimbursement since last April, Daewoong Pharmaceutical is expected to establish its position as a latecomer, Envlo, in
1
2
3
4
5
6
7
8
9
10
>